U.S. Physical Therapy Q3 2024 Results Overview
U.S. Physical Therapy, Inc. (NYSE: USPH), a leading provider of outpatient physical therapy clinics and services, recently released its financial results for the third quarter of 2024. The company's strong performance reflects its adaptability in a challenging environment, characterized by increased patient visits and strategic expansions within the business.
Financial Highlights
Revenue Growth and Earnings
For the three months ending September 30, 2024, U.S. Physical Therapy reported a total revenue of $142.7 million, which marks an impressive increase of $12.2 million or 9.3% compared to the third quarter of 2023. This growth is attributed to a rise in patient visits and the addition of new clinics into the company’s portfolio.
Adjusted EBITDA and Operating Results
The Adjusted EBITDA for this quarter stood at $21.1 million, showing a $2.5 million increase from $18.6 million in the previous year. Operating Results also saw positive growth, reaching $10.4 million in Q3 2024 compared to $9.2 million in the prior year, leading to a per-share increase from $0.62 to $0.69.
Net Income Analysis
Net income attributable to USPH’s shareholders was $6.6 million, with earnings per share recorded at $0.39. It's noteworthy that these figures include a significant charge of $2.5 million related to the closure of 32 clinics during the quarter. Adjusting for these closure costs, the net income would have been approximately $9.1 million.
Operational Statistics
Patient Visits and Clinic Expansion
Average patient visits per clinic reached a record high of 30.1 in the third quarter, up from 29.7 in the same period last year. The total patient visits during this quarter exceeded 1.3 million, reflecting a robust demand for outpatient physical therapy services.
During the quarter, U.S. Physical Therapy added 12 new clinics and strategically closed 32 clinics, optimizing its operational focus on higher-performing locations. As of September 30, 2024, the total number of owned and managed clinics increased to 700.
Industrial Injury Prevention Services
The company also reported a substantial improvement in its industrial injury prevention (IIP) services, with revenues for this sector growing to $25.3 million, a 29.9% increase from the previous year. The IIP gross profit rose to $5.6 million, demonstrating continued expansion in this critical service area.
Upcoming Strategic Plans
The management team, led by CEO Chris Reading, expressed optimism in the company’s direction moving forward. They highlighted the importance of the recent adjustments made to their operational portfolio and emphasized the ongoing demand for their services. The efforts to enhance reimbursement rates through improved contract negotiations are expected to yield further positive impacts on revenue as the company approaches 2025.
Dividend and Shareholder Returns
The Board of Directors declared a quarterly dividend of $0.44 per share, which will be payable on December 6, 2024, to shareholders on record by November 15, 2024. This marks a continued commitment to returning value to shareholders amidst the company's growth journey.
Looking Ahead
As U.S. Physical Therapy continues to adapt to an evolving healthcare landscape, the focus remains on strategic growth through acquisitions and clinic management. The company’s commitment to enhancing patient care and operational efficiency positions it well for a strong performance in upcoming quarters.
Frequently Asked Questions
What were the financial highlights of U.S. Physical Therapy in Q3 2024?
U.S. Physical Therapy reported $142.7 million in total revenue, a 9.3% increase from the prior year, and an adjusted EBITDA of $21.1 million.
How many clinics does U.S. Physical Therapy operate as of September 2024?
The company operates a total of 700 owned and managed clinics as of September 30, 2024.
What factors contributed to the growth in patient visits?
The growth in patient visits was supported by the addition of new clinics and a rise in demand for physical therapy services overall.
What was the company’s net income in Q3 2024?
The net income attributable to shareholders was $6.6 million, which included costs associated with the closure of clinics.
What is the company's dividend for shareholders in 2024?
The Board declared a quarterly dividend of $0.44 per share payable on December 6, 2024, reflecting a commitment to share value return.
